Quinoline-Based Antifungals

被引:222
作者
Musiol, R. [1 ]
Serda, M. [1 ]
Hensel-Bielowka, S. [1 ]
Polanski, J. [1 ]
机构
[1] Univ Silesia, Inst Chem, PL-40007 Katowice, Poland
关键词
Antifungals; allylamines; quinoline scaffold; mycoses; ALBICANS DIHYDROFOLATE-REDUCTASE; CANDIDA-ALBICANS; IN-VITRO; ANTIMICROBIAL ACTIVITIES; BIOLOGICAL EVALUATION; FUSARIUM INFECTION; FUNGAL-INFECTIONS; ACTIVITY SPECTRUM; AMPHOTERICIN-B; UNITED-STATES;
D O I
10.2174/092986710791163966
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although the assortment of antifungal drugs is broad, the most commonly used agents have major drawbacks. Toxicity, serious side effects or the emergence of drug resistance are amongst them. New drugs and drug candidates under clinical trials do not guarantee better pharmacological parameters. These new medicines may appear effective; however; they may cause serious side effects. This current review is focused on the recent findings in the design of quinoline based antifungal agents. This field seems to be especially interesting as 8-hydroxyquinoline and its metal complexes have been well known as antifungals for years. Structural similarities between quinoline based antifungals and allylamines or homoallylamines, e. g. terbinafine is another interesting fact. Quinoline can be identified in a number of synthetic and natural antifungals, which indicates nature's preference for this fragment and identifying it as one of the so-called privileged structures. We have discussed new trends in the design of quinolines with antifungal properties, their possible targets and the structure activity relationships within the antifungal series developed.
引用
收藏
页码:1960 / 1973
页数:14
相关论文
共 129 条
[1]  
Ablordeppey SY, 1999, CURR MED CHEM, V6, P1151
[2]  
ALBERT A, 1947, BRIT J EXP PATHOL, V28, P69
[3]  
ALBERT A, 1953, BRIT J EXP PATHOL, V34, P119
[4]  
Anaissie E, 1989, Infect Dis Clin North Am, V3, P867
[5]   The process of structure-based drug design [J].
Anderson, AC .
CHEMISTRY & BIOLOGY, 2003, 10 (09) :787-797
[6]  
[Anonymous], 2000, EMERG THER TARGET, DOI DOI 10.1517/14728222.4.3.265
[7]   Pharmacology of systemic antifungal agents [J].
Ashley, Elizabeth S. Dodds ;
Lewis, Russell ;
Lewis, James S. ;
Martin, Craig ;
Andes, David .
CLINICAL INFECTIOUS DISEASES, 2006, 43 :S28-S39
[8]   Primaquine therapy for malaria [J].
Baird, JK ;
Hoffman, SL .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (09) :1336-1345
[9]   ISOLATION OF LAVENDAMYCIN A NEW ANTIBIOTIC FROM STREPTOMYCES-LAVENDULAE [J].
BALITZ, DM ;
BUSH, JA ;
BRADNER, WT ;
DOYLE, TW ;
OHERRON, FA ;
NETTLETON, DE .
JOURNAL OF ANTIBIOTICS, 1982, 35 (03) :259-265
[10]   Simultaneous in vitro assay of the first four enzymes in the fungal aspartate pathway identifies a new class of aspartate kinase inhibitor [J].
Bareich, DC ;
Nazi, I ;
Wright, GD .
CHEMISTRY & BIOLOGY, 2003, 10 (10) :967-973